Video: Reengineering Drug Discovery With Recursion
Artificial intelligence enables the processing of datasets of unprecedented size and complexity to identify and prioritize novel drug candidates. We look for companies that can combine novel computational platforms with strong drug development expertise to develop potential breakthrough medicines.
Recursion Pharmaceuticals has developed a high throughput platform based on AI computer vision and coupled it with deep disease biology and chemistry to build a deep and data-rich pipeline. The company has initiated four clinical programs so far from a pipeline of dozens of pre-clinical programs. We invested in the Series B in 2017, and Recursion went public in 2021.